Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.
Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.
Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.
Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.
For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.
IMUNON (NASDAQ: IMNN) has announced a $10 million registered direct offering of its common stock, priced at-the-market under Nasdaq rules. The offering includes 5,000,000 registered shares at $2.00 per share, along with unregistered warrants to purchase up to 5,000,000 additional shares. The warrants have an exercise price of $2.00 per share and are exercisable immediately for 5.5 years. The company expects to close the offering around August 1, 2024, with H.C. Wainwright & Co. as the lead placement agent. IMUNON plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.
IMUNON announces positive topline results from the Phase 2 OVATION 2 Study of IMNN-001 in patients with advanced ovarian cancer. Key highlights include:
- 11.1-month increase in median overall survival (OS) compared to standard-of-care in the intent-to-treat population
- 15.7-month increase in median OS for patients receiving at least 20% of specified treatments
- Hazard ratio of 0.41 for patients also receiving PARP inhibitor therapy
- 3-month improvement in progression-free survival
IMUNON plans to initiate a Phase 3 registrational study in Q1 2025, pending FDA discussions.
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company, is set to announce topline results from its Phase 2 OVATION 2 Study on July 30, 2024, at 8:00 a.m. Eastern time. The study focuses on IMNN-001, the company's DNA-mediated immunotherapy for advanced ovarian cancer. IMNN-001 is an interleukin-12 (IL-12) immunotherapy based on IMUNON's TheraPlas™ technology.
Following the announcement, IMUNON will host an investment community conference call at 8:30 a.m. Eastern time to discuss the results and answer questions. Interested parties can participate by dialing 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll). A live webcast and replay of the call will be available, with the replay accessible until August 13, 2024.
IMUNON has announced the database lock for its Phase 2 OVATION 2 Study, which evaluates IMNN-001 in advanced ovarian cancer. The study, involving 110 patients, is assessing the safety, efficacy, and biological activity of IMNN-001 combined with neoadjuvant chemotherapy (NACT). The primary endpoint is Progression-Free Survival (PFS) and secondary endpoints include Overall Survival (OS). The independent statisticians have received the raw data and will analyze it per the Statistical Analysis Plan. IMUNON expects to release topline results by the end of July 2024. This study will guide the design of a planned Phase 3 trial.
IMUNON (NASDAQ: IMNN) has initiated the Phase 1 clinical trial for its IMNN-101 vaccine, a seasonal COVID-19 vaccine developed using its proprietary PlaCCine® DNA platform. The trial aims to evaluate the safety, tolerability, and immune response of the vaccine in 24 healthy volunteers, divided into three dosage groups. The study follows FDA guidelines to combat the SARS-CoV-2 Omicron XBB1.5 variant. IMUNON's preclinical data show promising results, with over 95% immunogenicity and stability at various temperatures. Topline data is expected by year-end 2024.
IMUNON (NASDAQ: IMNN) announced that an abstract detailing a Phase 2 study involving IMNN-001 combined with bevacizumab (Avastin) and neoadjuvant chemotherapy for advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation will occur on June 3, 2024, during the Gynecologic Cancer session at the event in Chicago, which runs from May 31 to June 4.
Lead investigator Dr. Amir A Jazaeri from The University of Texas MD Anderson Cancer Center will present the study, which aims to evaluate the effect of this combination therapy in newly diagnosed patients. The study is actively recruiting participants in the U.S. and is substantially funded by Break Through Cancer.
According to Dr. Sebastien Hazard, IMUNON’s Chief Medical Officer, the synergy observed between IMNN-001 and bevacizumab in pre-clinical experiments is promising, and the company aims to complete enrollment quickly to address this critical clinical question.
IMUNON, Inc. (NASDAQ: IMNN) announces the activation of the first site for its Phase 1 study with IMNN-101, a seasonal Covid-19 vaccine, utilizing its proprietary PlaCCine platform. The study aims to evaluate safety, tolerability, and immune response in healthy adults. Topline results are expected by year-end. IMNN-101 is designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, with potential advantages over mRNA vaccines in terms of immune protection and vaccine stability.
IMUNON, Inc. (NASDAQ: IMNN) reported financial results for Q1 2024, highlighting clinical development programs with promising results for IMNN-001 immunotherapy and PlaCCine modality. The company also appointed Dr. Stacy Lindborg as President and CEO. Recent developments include positive data in advanced ovarian cancer studies and progress in developing a seasonal COVID-19 booster vaccine. IMUNON received non-dilutive funding and reported a net loss of $4.9 million for Q1 2024.
IMUNON, Inc. (NASDAQ: IMNN) appointed Dr. Stacy R. Lindborg as President and CEO, bringing extensive experience in drug development. Dr. Lindborg takes over at a critical time with key clinical milestones approaching. IMNN-001 results in advanced ovarian cancer expected mid-summer, while Phase 1 data for IMNN-101 in seasonal COVID-19 are anticipated by year-end.
IMUNON, Inc. (NASDAQ: IMNN) will host a conference call on May 13, 2024, to discuss financial results for the first quarter of 2024. The company will provide updates on its clinical development programs, including IMNN-001 for ovarian cancer treatment and the PlaCCine modality for next-generation vaccines.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
